learn Spironolactone
powerful topical and oral anti-androgen used mostly by women
Search
forLearn
1 / 1 resultsResearch
5 / 1000+ results
research The Biology and Genomics of Human Hair Follicles: A Focus on Androgenetic Alopecia
Hair loss in Androgenetic Alopecia is caused by genetics, aging, and lifestyle, leading to hair follicle shrinkage and related health risks.
research Androgenic Disorders of Women: Diagnostic and Therapeutic Decision Making
The document concludes that proper diagnosis and tailored long-term treatment can effectively manage androgenic disorders in women, improving patient care outcomes.
research Established Risk Factors for Coronary Heart Disease Are Unrelated to Androgen-Induced Baldness in Female-to-Male Transsexuals
Baldness caused by male hormones in female-to-male transsexuals doesn't increase the risk of heart disease.
research Estimation of Serum Aldosterone, Free Testosterone, and DHEA-S and Scalp Androgen and Aldosterone Receptors in Female Androgenetic Alopecia: Is the Mystery Solved?
High aldosterone and free testosterone levels link to female hair loss; testing aldosterone may predict hypertension risk.
research Analysis of Androgen Receptor Expression and Activity in the Mouse Brain
Androgen receptors in the mouse brain may explain cognitive and mood changes in prostate cancer treatment.
Community Join
5 / 1000+ resultscommunity Anyone excited for CosmeRNA coming this month?
CosmeRNA, a new hair loss treatment, is expected to release soon and may become part of the "big three" treatments alongside finasteride and minoxidil. It works differently from finasteride by targeting androgen receptors in hair follicles, potentially offering fewer side effects.
community Protac degradation of the androgen receptor in mice shows good efficacy and no systemic drug could be found
The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.
community Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China
Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.
community Pyrilutamide Phase 3 on its way
Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.
community My Pyrilutamide Experience so far
A user's experience with Pyrilutamide for hair loss, which has been successful in reversing receding hairline when part of their stack with other treatments such as Dutasteride, Minoxidil, and Ketoconazole shampoo.